Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
CPT: Pharmacometrics & Systems Pharmacology|May 24, 2023
Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosisRussell Wada, Huub Jan Kleijn, Lu Zhang, et al.
Frontiers in Neurology|November 22, 2021
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum DisorderPratap Singh, Xiang Gao, Huub Jan Kleijn, et al.
Clinical Therapeutics|March 11, 2023
Predicted Bezlotoxumab Exposure in Patients Who Have Received a Hematopoietic Stem Cell TransplantCamila de Almeida, Michael Wong, Huub Jan Kleijn, et al.
Frontiers in Neurology|November 19, 2021
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia GravisJonathan P R Monteleone, Xiang Gao, Huub Jan Kleijn, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 13, 2020
A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrenceKa Lai Yee, Huub Jan Kleijn, Stefan Zajic, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2018
Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile InfectionKa Lai Yee, Huub Jan Kleijn, Thomas Kerbusch, et al.
Clinical and Translational Science|November 10, 2025
Exposure-Response Analysis of Donidalorsen for the Treatment of Hereditary AngioedemaPratap Singh, Han Witjes, Huub Jan Kleijn, et al.
Clinical and Translational Science|January 25, 2021
Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignanciesXuemin Jiang, Russ Wada, Bill Poland, et al.
Clinical Pharmacology and Therapeutics|October 1, 2023
Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckYulia Vugmeyster, Abhigyan Ravula, Elisabeth Rouits, et al.
Clinical and Translational Science|November 3, 2025
Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing DialysisVenkateswari Y Muthukrishnan, Thomas Kerbusch, Laura E Strong, et al.
Pageof 2